Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 18/20 | 0.66 |
| ▸ | HSD17B1 | P14061 | 9/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22867348 | 1.00 | HSD17B2 (0.66) | HSD17B2HSD17B1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL22867848 | 0.93 | HSD17B2 (0.73) | HSD17B2HSD17B1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL22867853 | 0.86 | HSD17B2 (0.76) | HSD17B2HSD17B1 | |
| SCHEMBL22867971 | 0.86 | HSD17B2 (0.63) | HSD17B2HSD17B1 | |
| SCHEMBL22867493 | 0.85 | HSD17B2 (0.62) | HSD17B2HSD17B1 | |
| SCHEMBL22867861 | 0.85 | HSD17B2 (0.62) | HSD17B2HSD17B1 | |
| SCHEMBL30359677 | 0.85 | HSD17B2 (0.73) | HSD17B2HSD17B1 | |
| SCHEMBL22867747 | 0.85 | HSD17B2 (0.73) | HSD17B2HSD17B1 | |
| SCHEMBL22867750 | 0.85 | HSD17B2 (0.73) | HSD17B2HSD17B1 | |
| SCHEMBL22867584 | 0.84 | HSD17B2 (0.60) | HSD17B2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | HSD17B2 5/4885HSD17B1 3/4885TAS1R3 4634/4885 |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | HSD17B2 5/4885HSD17B1 3/4885TAS1R3 4634/4885 |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | HSD17B3, HSD17B11, HSD17B1 | HSD17B2 5/4885HSD17B1 3/4885TAS1R3 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.